학술논문

The Host-Microbiome Response to Hyperbaric Oxygen Therapy in Ulcerative Colitis Patients
Document Type
article
Source
Cellular and Molecular Gastroenterology and Hepatology. 14(1)
Subject
Biological Sciences
Biomedical and Clinical Sciences
Microbiology
Clinical Sciences
Medical Biochemistry and Metabolomics
Inflammatory Bowel Disease
Nutrition
Clinical Research
Biotechnology
Genetics
Autoimmune Disease
Digestive Diseases
Animals
Colitis
Ulcerative
Humans
Hyperbaric Oxygenation
Interleukin-10
Mice
Microbiota
RNA
Ribosomal
16S
Biochemistry and cell biology
Clinical sciences
Language
Abstract
Background & aimsHyperbaric oxygen therapy (HBOT) is a promising treatment for moderate-to-severe ulcerative colitis. However, our current understanding of the host and microbial response to HBOT remains unclear. This study examined the molecular mechanisms underpinning HBOT using a multi-omic strategy.MethodsPre- and post-intervention mucosal biopsies, tissue, and fecal samples were collected from HBOT phase 2 clinical trials. Biopsies and fecal samples were subjected to shotgun metaproteomics, metabolomics, 16s rRNA sequencing, and metagenomics. Tissue was subjected to bulk RNA sequencing and digital spatial profiling (DSP) for single-cell RNA and protein analysis, and immunohistochemistry was performed. Fecal samples were also used for colonization experiments in IL10-/- germ-free UC mouse models.ResultsProteomics identified negative associations between HBOT response and neutrophil azurophilic granule abundance. DSP identified an HBOT-specific reduction of neutrophil STAT3, which was confirmed by immunohistochemistry. HBOT decreased microbial diversity with a proportional increase in Firmicutes and a secondary bile acid lithocholic acid. A major source of the reduction in diversity was the loss of mucus-adherent taxa, resulting in increased MUC2 levels post-HBOT. Targeted database searching revealed strain-level associations between Akkermansia muciniphila and HBOT response status. Colonization of IL10-/- with stool obtained from HBOT responders resulted in lower colitis activity compared with non-responders, with no differences in STAT3 expression, suggesting complementary but independent host and microbial responses.ConclusionsHBOT reduces host neutrophil STAT3 and azurophilic granule activity in UC patients and changes in microbial composition and metabolism in ways that improve colitis activity. Intestinal microbiota, especially strain level variations in A muciniphila, may contribute to HBOT non-response.